Biohaven Ltd. (NYSE: BHVN) announced today that it presented clinical safety and efficacy data for BHV-1510 at the 2025 ...
MedPage Today on MSN
The Latest on Emerging Therapies for Metastatic HR+/HER2- Breast Cancer
Trastuzumab deruxtecan (T-DXd; Enhertu), is a HER2-targeting ADC that is used in ET-treated HER2-low or HER2-ultralow disease and offered meaningful results in DESTINY-Breast04. In a 2025 real-world ...
News-Medical.Net on MSN
Everyday PFAS exposure alters placental function in early pregnancy
By Dr. Priyom Bose, Ph.D. By modelling real-world PFAS mixtures found in first-trimester placentas, researchers reveal how ...
Most studies rely on forever chemicals detected late in pregnancy or cell models, so do not reflect real-life exposure ...
A new study published in the Journal of Cannabis Research and U.S. Library of Medicine reports that cannabidiol may reduce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback